Claiming historic first, AstraZeneca says Enhertu aces PhIII for hard-to-reach segment of patients
AstraZeneca has racked up a crucial Phase III win for its megablockbuster prospect Enhertu — one that could push the drug to unchartered places currently unreachable for its peers.
For a while now, the pharma giant has been talking about how its third-gen antibody drug conjugate, developed in a $6.9 billion partnership with Daiichi Sankyo, could do a better job going after tumors marked by various levels of HER2 expression — even those that would traditionally be described as “HER2-low.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.